Amedeo Smart

Free Medical Literature Service


 

Amedeo

Dermatology

  Free Subscription

Articles published in
Cancer
    September 2021
  1. BETH NIERENGARTEN M
    Preclinical data suggest role of dopamine in preventing select skin cancers.
    Cancer. 2021;127:3053.
    >> Share

    August 2021
  2. AMIT M, Liu C, Mansour J, Gleber-Netto FO, et al
    Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33773.
    >> Share

    July 2021
  3. MACARTHUR KM, Baumann BC, Sobanko JF, Etzkorn JR, et al
    Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33651.
    >> Share

  4. PAPPO AS, McPherson V, Pan H, Wang F, et al
    A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions.
    Cancer. 2021 Jul 6. doi: 10.1002/cncr.33750.
    >> Share

  5. SONDAK VK, Messina JL
    What's new in pediatric melanoma and Spitz tumors? Pretty much everything.
    Cancer. 2021 Jul 6. doi: 10.1002/cncr.33749.
    >> Share

    May 2021
  6. PRINTZ C
    Cutaneous Melanoma Overdiagnosed, Researchers Find.
    Cancer. 2021;127:1547.
    >> Share

  7. TAYLOR LA, Eguchi MM, Reisch LM, Radick AC, et al
    Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?
    Cancer. 2021 May 4. doi: 10.1002/cncr.33612.
    >> Share

    April 2021
  8. GOGEBAKAN KC, Mukherjee K, Berry EG, Sonmez K, et al
    Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33515.
    >> Share

  9. ESKANDER A, Marqueen KE, Edwards HA, Joshua AM, et al
    To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma.
    Cancer. 2021 Apr 12. doi: 10.1002/cncr.33499.
    >> Share

  10. BROMAN KK, Hughes T, Dossett L, Sun J, et al
    Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2).
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33483.
    >> Share

  11. GERSHENWALD JE
    Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned ... and still learning.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33484.
    >> Share

  12. SADIGH G, Gray RJ, Sparano JA, Yanez B, et al
    Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33527.
    >> Share

    March 2021
  13. KEMPF E, Zalcman G, Lebbe C
    National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?
    Cancer. 2021 Mar 31. doi: 10.1002/cncr.33495.
    >> Share

  14. CHRISTEN C, Belgodere L, Guillot B, Jumeau C, et al
    Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33492.
    >> Share

  15. BANDER ED, Yuan M, Carnevale JA, Reiner AS, et al
    Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Cancer. 2021 Mar 2. doi: 10.1002/cncr.33459.
    >> Share

    February 2021
  16. NYANTE SJ, Benefield TS, Kuzmiak CM, Earnhardt K, et al
    Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures.
    Cancer. 2021 Feb 26. doi: 10.1002/cncr.33460.
    >> Share

    January 2021
  17. PRINTZ C
    Drug shows significant early promise in early, high-risk, HR-positive, HER2-negative breast cancer: Interim data indicate that adding abemaciclib to hormonal therapy reduces recurrence risk.
    Cancer. 2021;127:169-170.
    >> Share

    December 2020
  18. AMIT M, Liu C, Gleber-Netto FO, Kini S, et al
    Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2020 Dec 15. doi: 10.1002/cncr.33373.
    >> Share

  19. PRINTZ C
    Early breast cancer screening in childhood cancer survivors treated with chest radiation may reduce deaths by more than 50.
    Cancer. 2020;126:5197.
    >> Share

    November 2020
  20. KARAPETYAN L, Yang X, Wang H, Sander CA, et al
    Indoor tanning exposure in association with multiple primary melanoma.
    Cancer. 2020 Nov 10. doi: 10.1002/cncr.33307.
    >> Share

    October 2020
  21. PASKETT ED, Le-Rademacher J, Oliveri JM, Liu H, et al
    A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).
    Cancer. 2020 Oct 20. doi: 10.1002/cncr.33183.
    >> Share

  22. NAUGHTON MJ, Liu H, Seisler DK, Le-Rademacher J, et al
    Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients.
    Cancer. 2020 Oct 20. doi: 10.1002/cncr.33184.
    >> Share

  23. YIN K, Singh P, Drohan B, Hughes KS, et al
    Breast imaging, breast surgery, and cancer genetics in the age of COVID-19.
    Cancer. 2020;126:4466-4472.
    >> Share

    September 2020
  24. GREENE N, Malone J, Adams MA, Dean LT, et al
    "This is some mess right here": Exploring interactions between Black sexual minority women and health care providers for breast cancer screening and care.
    Cancer. 2020 Sep 29. doi: 10.1002/cncr.33219.
    >> Share

  25. EMERSON MA, Golightly YM, Aiello AE, Reeder-Hayes KE, et al
    Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women.
    Cancer. 2020 Sep 21. doi: 10.1002/cncr.33121.
    >> Share

  26. PRINTZ C
    TAILORx study finds early, abrupt cognitive decline among patients with breast cancer.
    Cancer. 2020;126:4083.
    >> Share

  27. QIAN JM, Martin AM, Martin K, Hammoudeh L, et al
    Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33196.
    >> Share

  28. MARMOR S, Longacre CF, Altman AM, Hui JYC, et al
    Genomic expression assay testing among American Indian and Alaska Native women with breast cancer.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33150.
    >> Share

  29. PENG SM, Yang KC, Chan WP, Wang YW, et al
    Impact of the COVID-19 pandemic on a population-based breast cancer screening program.
    Cancer. 2020 Sep 11. doi: 10.1002/cncr.33180.
    >> Share

    August 2020
  30. KHURI FR, O'Regan RM
    Progress in breast cancer research amid the COVID-19 gloom.
    Cancer. 2020;126 Suppl 16:3809-3810.
    >> Share

  31. AN X, Lei X, Huang R, Luo R, et al
    Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
    Cancer. 2020;126 Suppl 16:3837-3846.
    >> Share

  32. YANG H, Zhang S, Liu P, Cheng L, et al
    Use of high-resolution full-field optical coherence tomography and dynamic cell imaging for rapid intraoperative diagnosis during breast cancer surgery.
    Cancer. 2020;126 Suppl 16:3847-3856.
    >> Share

  33. GUO R, Su Y, Si J, Xue J, et al
    A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases.
    Cancer. 2020;126 Suppl 16:3819-3829.
    >> Share

  34. TANG Y, Zhang YJ, Zhang N, Shi M, et al
    Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes.
    Cancer. 2020;126 Suppl 16:3857-3866.
    >> Share

  35. PAN H, Zhang K, Wang M, Ling L, et al
    The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population-based observational study.
    Cancer. 2020;126 Suppl 16:3830-3836.
    >> Share

  36. XU B, Hu X, Feng J, Geng C, et al
    Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
    Cancer. 2020;126 Suppl 16:3867-3882.
    >> Share

  37. FAN Y, Xu B
    Current clinical trials on breast cancer in China: A systematic literature review.
    Cancer. 2020;126 Suppl 16:3811-3818.
    >> Share

  38. KASHANI-SABET M, Miller JR 3rd, Lo S, Nosrati M, et al
    Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system.
    Cancer. 2020 Aug 11. doi: 10.1002/cncr.33088.
    >> Share

  39. CHRISTGEN M, Gluz O, Harbeck N, Kates RE, et al
    Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
    Cancer. 2020 Aug 11. doi: 10.1002/cncr.33104.
    >> Share

  40. KIM EY, Chang Y, Ahn J, Yun JS, et al
    Mammographic breast density, its changes, and breast cancer risk in premenopausal and postmenopausal women.
    Cancer. 2020 Aug 7. doi: 10.1002/cncr.33138.
    >> Share

  41. PAN IW, Yen TWF, Huo J, Chen C, et al
    Choice of local therapy for young women with early-stage breast cancer who have young-aged children.
    Cancer. 2020 Aug 5. doi: 10.1002/cncr.33099.
    >> Share

    July 2020
  42. KUNTE S, Abraham J, Montero AJ
    Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
    Cancer. 2020 Jul 28. doi: 10.1002/cncr.33102.
    >> Share

  43. PRINTZ C
    Research notes largest yearly decline in melanoma deaths.
    Cancer. 2020;126:3173.
    >> Share

  44. TROGDON JG, Liu X, Reeder-Hayes KE, Rotter J, et al
    Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.
    Cancer. 2020 Jul 10. doi: 10.1002/cncr.33077.
    >> Share

  45. SHEPPARD VB, Dash C, Nomura S, Sutton AL, et al
    Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Cancer. 2020 Jul 2. doi: 10.1002/cncr.33054.
    >> Share

  46. PRINTZ C
    Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.
    Cancer. 2020;126:2955.
    >> Share

    June 2020
  47. SUAREZ-ALMAZOR ME, Herrera R, Lei X, Chavez-MacGregor M, et al
    Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.
    Cancer. 2020 Jun 23. doi: 10.1002/cncr.33035.
    >> Share

  48. PAN K, Chlebowski RT, Mortimer JE, Gunther MJ, et al
    Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative.
    Cancer. 2020 Jun 12. doi: 10.1002/cncr.33002.
    >> Share

  49. IBRAHEEM A, Olopade OI, Huo D
    Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
    Cancer. 2020 Jun 10. doi: 10.1002/cncr.32956.
    >> Share

  50. DANCIU OC, Chen Z, Hoskins KF
    If you don't measure it, you can't improve it: Success and shortcomings of genomic assays in early breast cancer.
    Cancer. 2020 Jun 10. doi: 10.1002/cncr.32955.
    >> Share

  51. MA S, Shepard DS, Ritter GA, Martell RE, et al
    The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32976.
    >> Share

  52. BAUMANN BC, MacArthur KM, Brewer JD, Mendenhall WM, et al
    Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.
    Cancer. 2020 Jun 1. doi: 10.1002/cncr.32969.
    >> Share


  53. The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors.
    Cancer. 2020;126:2566-2570.
    >> Share

    May 2020
  54. PATRINELY JR JR, Baker LX, Davis EJ, Song H, et al
    Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Cancer. 2020 May 28. doi: 10.1002/cncr.32984.
    >> Share

  55. CACHO-DIAZ B, Salmeron-Moreno K, Alvarez-Alvarez A, Mendoza-Olivas LG, et al
    Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.
    Cancer. 2020 May 26. doi: 10.1002/cncr.32928.
    >> Share

  56. SHARIFI MN, Anandan A, Grogan P, O'Regan RM, et al
    Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
    Cancer. 2020 May 19. doi: 10.1002/cncr.32931.
    >> Share

  57. PRINTZ C
    Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2-positive breast cancer.
    Cancer. 2020;126:2113.
    >> Share

  58. HENLEY SJ, Thomas CC, Lewis DR, Ward EM, et al
    Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers.
    Cancer. 2020;126:2250-2266.
    >> Share

  59. ARORA M, Chen Y, Hageman L, Wu J, et al
    Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.
    Cancer. 2020 May 15. doi: 10.1002/cncr.32941.
    >> Share

  60. ROSITCH AF, Unger-Saldana K, DeBoer RJ, Ng'ang'a A, et al
    The role of dissemination and implementation science in global breast cancer control programs: Frameworks, methods, and examples.
    Cancer. 2020;126 Suppl 10:2394-2404.
    >> Share

  61. MUTEBI M, Anderson BO, Duggan C, Adebamowo C, et al
    Breast cancer treatment: A phased approach to implementation.
    Cancer. 2020;126 Suppl 10:2365-2378.
    >> Share

  62. DVALADZE A, Kizub DA, Cabanes A, Nakigudde G, et al
    Breast cancer patient advocacy: A qualitative study of the challenges and opportunities for civil society organizations in low-income and middle-income countries.
    Cancer. 2020;126 Suppl 10:2439-2447.
    >> Share

  63. HORTON S, Camacho Rodriguez R, Anderson BO, Aung S, et al
    Health system strengthening: Integration of breast cancer care for improved outcomes.
    Cancer. 2020;126 Suppl 10:2353-2364.
    >> Share

  64. GINSBURG O, Yip CH, Brooks A, Cabanes A, et al
    Breast cancer early detection: A phased approach to implementation.
    Cancer. 2020;126 Suppl 10:2379-2393.
    >> Share

  65. HENDERSON V, Tossas-Milligan K, Martinez E, Williams B, et al
    Implementation of an integrated framework for a breast cancer screening and navigation program for women from underresourced communities.
    Cancer. 2020;126 Suppl 10:2481-2493.
    >> Share

  66. SCHEEL JR, Giglou MJ, Segel S, Orem J, et al
    Breast cancer early detection and diagnostic capacity in Uganda.
    Cancer. 2020;126 Suppl 10:2469-2480.
    >> Share

  67. DVALADZE A, Duggan C, Anderson BO
    Phased implementation for breast cancer management in low-income and middle-income countries: A proposal for the strategic application of resource-stratified guidelines by the Breast Health Global Initiative.
    Cancer. 2020;126 Suppl 10:2337-2338.
    >> Share

  68. MA D, Jiang YZ, Xiao Y, Xie MD, et al
    Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Cancer. 2020 May 8. doi: 10.1002/cncr.32922.
    >> Share

  69. BROWN LC, Murphy AR, Lalonde CS, Subhedar PD, et al
    Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function.
    Cancer. 2020 May 6. doi: 10.1002/cncr.32934.
    >> Share

    April 2020
  70. ZHOU J, Wang H, Fu F, Li Z, et al
    Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Cancer. 2020 Apr 27. doi: 10.1002/cncr.32905.
    >> Share

  71. NYROP KA, Deal AM, Reeve BB, Basch E, et al
    Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.
    Cancer. 2020 Apr 21. doi: 10.1002/cncr.32898.
    >> Share

  72. MAHORTER SS, Knerr S, Bowles EJA, Wernli KJ, et al
    Prior breast density awareness, knowledge, and communication in a health system-embedded behavioral intervention trial.
    Cancer. 2020;126:1614-1621.
    >> Share

  73. REIS JC, Travado L, Antoni MH, Oliveira FPM, et al
    Negative affect and stress-related brain metabolism in patients with metastatic breast cancer.
    Cancer. 2020 Apr 14. doi: 10.1002/cncr.32902.
    >> Share

  74. CONTE P, Schneeweiss A, Loibl S, Mamounas EP, et al
    Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Cancer. 2020 Apr 14. doi: 10.1002/cncr.32873.
    >> Share

  75. HILD S, Johanet M, Valenza A, Thabaud M, et al
    Quality of decision aids developed for women at average risk of breast cancer eligible for mammographic screening: Systematic review and assessment according to the international patient decision aid standards instrument.
    Cancer. 2020 Apr 8. doi: 10.1002/cncr.32858.
    >> Share

  76. FARVID MS, Spence ND, Holmes MD, Barnett JB, et al
    Fiber consumption and breast cancer incidence: A systematic review and meta-analysis of prospective studies.
    Cancer. 2020 Apr 6. doi: 10.1002/cncr.32816.
    >> Share

    March 2020
  77. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Prentice RL, et al
    Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women.
    Cancer. 2020 Mar 25. doi: 10.1002/cncr.32846.
    >> Share

  78. SHARIFF-MARCO S, Gomez SL, Canchola AJ, Fullington H, et al
    Nativity, ethnic enclave residence, and breast cancer survival among Latinas: Variations between California and Texas.
    Cancer. 2020 Mar 17. doi: 10.1002/cncr.32845.
    >> Share

  79. MOLINA G, Kasumova GG, Qadan M, Boland GM, et al
    Use of immunotherapy and surgery for stage IV melanoma.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32817.
    >> Share

  80. HERCULES SM, Hercules JC, Ansari A, Date SAJ, et al
    High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32771.
    >> Share

  81. MUKAMA T, Kharazmi E, Sundquist K, Sundquist J, et al
    Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32815.
    >> Share

  82. CHEN L, Alexanderson KAE
    Trajectories of sickness absence and disability pension in the 2 years before and 3 years after breast cancer diagnosis: A Swedish longitudinal population-based cohort study.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32820.
    >> Share

  83. PRINTZ C
    First person profile: Dennis J. Slamon, MD, PhD: Dr. Slamon's pioneering work helped lead to the breakthrough breast cancer drug trastuzumab, which has saved and extended the lives of millions of patients.
    Cancer. 2020;126:919-920.
    >> Share

    February 2020
  84. AVIS NE, Levine B, Goyal N, Crawford SL, et al
    Health-related quality of life among breast cancer survivors and noncancer controls over 10 years: Pink SWAN.
    Cancer. 2020 Feb 27. doi: 10.1002/cncr.32757.
    >> Share

  85. PETERSON LL, Park S, Park Y, Colditz GA, et al
    Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the National Institutes of Health-AARP Diet and Health Study.
    Cancer. 2020 Feb 25. doi: 10.1002/cncr.32798.
    >> Share

  86. PRINTZ C
    Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    Cancer. 2020;126:693.
    >> Share

  87. XU Z, Tian S, Kong LQ
    On the proportion of male breast cancer among all breast cancers.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32731.
    >> Share

  88. YADAV S, Karam D, Bin Riaz I, Xie H, et al
    Reply to On the proportion of male breast cancer among all breast cancers.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32727.
    >> Share

  89. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
    Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Cancer. 2020;126:549-558.
    >> Share

    January 2020
  90. JATOI I
    Residual confounding threatens the validity of observational studies on breast cancer local therapy.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32741.
    >> Share

  91. KURIAN AW, Canchola AJ, Gomez SL
    Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32743.
    >> Share

  92. WEIDNER AE, Liggin ME, Zuniga BI, Tezak AL, et al
    Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    Cancer. 2020 Jan 22. doi: 10.1002/cncr.32715.
    >> Share

  93. SONG Y, Barry WT, Seah DS, Tung NM, et al
    Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Cancer. 2020;126:271-280.
    >> Share

  94. WANG LX, Quach HT, Moodabigil NV, Davis EJ, et al
    Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Cancer. 2020;126:322-328.
    >> Share

  95. GUO F, Scholl M, Fuchs EL, Berenson AB, et al
    BRCA testing in unaffected young women in the United States, 2006-2017.
    Cancer. 2020;126:337-343.
    >> Share

  96. CLOUGH L, Bayakly AR, Ward KC, Khan MK, et al
    Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia.
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32665.
    >> Share

  97. HERSHMAN DL, Accordino MK, Shen S, Buono D, et al
    Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events.
    Cancer. 2020 Jan 8. doi: 10.1002/cncr.32690.
    >> Share

  98. SHIN DW, Yu J, Cho J, Lee SK, et al
    Breast cancer screening disparities between women with and without disabilities: A national database study in South Korea.
    Cancer. 2020 Jan 6. doi: 10.1002/cncr.32693.
    >> Share

  99. PRINTZ C
    Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement.
    Cancer. 2020;126:1827.
    >> Share

    December 2019
  100. POKLEPOVIC AS, Luke JJ
    Considering adjuvant therapy for stage II melanoma.
    Cancer. 2019 Dec 23. doi: 10.1002/cncr.32585.
    >> Share

  101. DOWNS-CANNER SM, Gaber CE, Louie RJ, Strassle PD, et al
    Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32668.
    >> Share

  102. MANDELBLATT JS, Zhai W, Ahn J, Small BJ, et al
    Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32663.
    >> Share

  103. PAPAKONSTANTINOU A, Matikas A, Bengtsson NO, Malmstrom P, et al
    Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial.
    Cancer. 2019 Dec 18. doi: 10.1002/cncr.32653.
    >> Share

  104. ROBERTS AW, Fergestrom N, Neuner JM, Winn AN, et al
    New-onset persistent opioid use following breast cancer treatment in older adult women.
    Cancer. 2019 Dec 17. doi: 10.1002/cncr.32593.
    >> Share

  105. AFIFI AM, Saad AM, Al-Husseini MJ, Elmehrath AO, et al
    Causes of death after breast cancer diagnosis: A US population-based analysis.
    Cancer. 2019 Dec 16. doi: 10.1002/cncr.32648.
    >> Share

  106. HUMPHRIES B, Lauzier S, Drolet M, Coyle D, et al
    Wage losses among spouses of women with nonmetastatic breast cancer.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32638.
    >> Share

    November 2019
  107. ZHANG H, Zhu H, Deng G, Zito CR, et al
    PLEKHA5 regulates tumor growth in metastatic melanoma.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32611.
    >> Share

  108. LE D, Speers C, Thompson L, Gondara L, et al
    The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Cancer. 2019 Nov 21. doi: 10.1002/cncr.32631.
    >> Share

  109. KURIAN AW, Canchola AJ, Ma CS, Clarke CA, et al
    Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015.
    Cancer. 2019 Nov 21. doi: 10.1002/cncr.32618.
    >> Share

  110. HO AY, Barker CA, Arnold BB, Powell SN, et al
    A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
    Cancer. 2019 Nov 20. doi: 10.1002/cncr.32599.
    >> Share

  111. RAMIREZ AG, Choi BY, Munoz E, Perez A, et al
    Assessing the effect of patient navigator assistance for psychosocial support services on health-related quality of life in a randomized clinical trial in Latino breast, prostate, and colorectal cancer survivors.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32626.
    >> Share

  112. BOWEN DJ, Shinn EH, Gregrowski S, Kimmick G, et al
    Patient-reported outcomes in the Translational Breast Cancer Research Consortium.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32615.
    >> Share

  113. COHEN JV, Wang N, Venur VA, Hadfield MJ, et al
    Neurologic complications of melanoma.
    Cancer. 2019 Nov 14. doi: 10.1002/cncr.32619.
    >> Share

  114. ABUDU B, Cook KA, Gershenwald JE, Cohen PR, et al
    Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32587.
    >> Share

  115. IM EO, Kim S, Yang YL, Chee W, et al
    The efficacy of a technology-based information and coaching/support program on pain and symptoms in Asian American survivors of breast cancer.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32579.
    >> Share

    October 2019
  116. HOLBROOK K, Lutzky J, Davies MA, Davis JM, et al
    Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Cancer. 2019 Oct 28. doi: 10.1002/cncr.32547.
    >> Share

  117. KANDEL M, Dalle S, Bardet A, Allayous C, et al
    Quality-of-life assessment in French patients with metastatic melanoma in real life.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32554.
    >> Share

  118. MALMGREN JA, Calip GS, Atwood MK, Mayer M, et al
    Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32531.
    >> Share

  119. LETOURNEAU JM, Wald K, Sinha N, Juarez-Hernandez F, et al
    Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32546.
    >> Share

  120. YADAV S, Karam D, Bin Riaz I, Xie H, et al
    Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century.
    Cancer. 2019 Oct 7. doi: 10.1002/cncr.32472.
    >> Share

  121. PIRES DA SILVA I, Lo S, Quek C, Gonzalez M, et al
    Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Cancer. 2019 Oct 4. doi: 10.1002/cncr.32522.
    >> Share

  122. BARTLETT EK, Flynn JR, Panageas KS, Ferraro RA, et al
    High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Cancer. 2019 Oct 4. doi: 10.1002/cncr.32506.
    >> Share

  123. PRINTZ C
    Some elderly survivors of 3 common cancers have an increased risk of brain metastases.
    Cancer. 2019;125:3286-3287.
    >> Share

    September 2019
  124. HALEY JS, Hibler EA, Zhou S, Schmitz KH, et al
    Dose-dependent effect of aerobic exercise on inflammatory biomarkers in a randomized controlled trial of women at high risk of breast cancer.
    Cancer. 2019 Sep 30. doi: 10.1002/cncr.32530.
    >> Share

  125. CARROLL JE, Small BJ, Tometich DB, Zhai W, et al
    Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype.
    Cancer. 2019 Sep 25. doi: 10.1002/cncr.32489.
    >> Share

  126. JOHNS SA, Stutz PV, Talib TL, Cohee AA, et al
    Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.
    Cancer. 2019 Sep 20. doi: 10.1002/cncr.32518.
    >> Share

  127. PRINTZ C
    First person profile: Leslie Bernstein, PhD: An epidemiologist known for her groundbreaking discoveries about breast cancer, Dr. Bernstein continues to push the field forward.
    Cancer. 2019;125:2907-2909.
    >> Share

    August 2019
  128. EWER SM, Pham DD
    Late-onset heart failure after treatment for breast cancer.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32483.
    >> Share

  129. LEE J, Hur H, Lee JW, Youn HJ, et al
    Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32485.
    >> Share

  130. FREUND KM, Haas JS, Lemon SC, Burns White K, et al
    Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.
    Cancer. 2019 Aug 26. doi: 10.1002/cncr.32432.
    >> Share

  131. METCALFE KA, Retrouvey H, Kerrebijn I, Butler K, et al
    Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer.
    Cancer. 2019 Aug 22. doi: 10.1002/cncr.32405.
    >> Share

  132. MALECKI KMC
    Epigenetics and differential effects of aspirin on breast cancer survival: Opportunities for understanding human susceptibility and risk.
    Cancer. 2019 Aug 12. doi: 10.1002/cncr.32365.
    >> Share

  133. WANG T, McCullough LE, White AJ, Bradshaw PT, et al
    Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
    Cancer. 2019 Aug 12. doi: 10.1002/cncr.32364.
    >> Share

  134. SCHVARTSMAN G, Ma J, Bassett RL Jr, Haydu LE, et al
    Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454.
    >> Share

  135. REEDER-HAYES KE, Mayer SE, Olshan AF, Wheeler SB, et al
    Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32378.
    >> Share

  136. MILES RC, Lehman CD, Mercaldo SF, Tamimi RM, et al
    Obesity and breast cancer screening: Cross-sectional survey results from the behavioral risk factor surveillance system.
    Cancer. 2019 Aug 8. doi: 10.1002/cncr.32430.
    >> Share

  137. MANZ CR
    Getting in sync with adherence to endocrine therapy in breast cancer.
    Cancer. 2019 Aug 2. doi: 10.1002/cncr.32434.
    >> Share

  138. NEUNER JM, Fergestrom NM, Laud PW, Nattinger AB, et al
    The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.
    Cancer. 2019 Aug 2. doi: 10.1002/cncr.32433.
    >> Share


  139. Erratum: Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18-44.
    Cancer. 2019;125:2706.
    >> Share

    July 2019
  140. LEE CT, Lehrer EJ, Aphale A, Lango M, et al
    Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32371.
    >> Share

  141. PEREZ EA, Barrios C, Eiermann W, Toi M, et al
    Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Cancer. 2019 Jul 18. doi: 10.1002/cncr.32392.
    >> Share

  142. DUSTIN D, Gu G, Fuqua SAW
    ESR1 mutations in breast cancer.
    Cancer. 2019 Jul 18. doi: 10.1002/cncr.32345.
    >> Share

  143. PRINTZ C
    Study: Patients with HER2-positive, stage IV breast cancer experienced better survival with surgery.
    Cancer. 2019;125:2337.
    >> Share

  144. RULLI E, Legramandi L, Salvati L, Mandala M, et al
    The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32375.
    >> Share

  145. SCOTT LC, Mobley LR, Kuo TM, Il'yasova D, et al
    Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.
    Cancer. 2019 Jul 8. doi: 10.1002/cncr.32207.
    >> Share

    June 2019
  146. NAROD SA
    Genetic testing for breast cancer in the Hispanic community.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32334.
    >> Share

  147. MEISEL JL, O'Regan RM
    Race, breast cancer, and prognosis: Where biology is queen?
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32294.
    >> Share

  148. WEITZEL JN, Neuhausen SL, Adamson A, Tao S, et al
    Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32083.
    >> Share

  149. WALSH SM, Zabor EC, Stempel M, Morrow M, et al
    Does race predict survival for women with invasive breast cancer?
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32296.
    >> Share

  150. MORI M, Fujimori M, van Vliet LM, Yamaguchi T, et al
    Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601).
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32327.
    >> Share

  151. LILLEBORGE M, Falk RS, Russnes H, Sauer T, et al
    Risk of breast cancer by prior screening results among women participating in BreastScreen Norway.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32330.
    >> Share

  152. SUNG H, DeSantis CE, Fedewa SA, Kantelhardt EJ, et al
    Breast cancer subtypes among Eastern-African-born black women and other black women in the United States.
    Cancer. 2019 Jun 13. doi: 10.1002/cncr.32293.
    >> Share

  153. KAMBHAMPATI S, Bauer KE, Bracci PM, Keenan BP, et al
    Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32206.
    >> Share

    May 2019
  154. FAYANJU OM, Yenokyan K, Ren Y, Goldstein BA, et al
    The effect of treatment on patient-reported distress after breast cancer diagnosis.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32174.
    >> Share

  155. WASSERMANN J, Gelber SI, Rosenberg SM, Ruddy KJ, et al
    Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32192.
    >> Share

  156. HENRY NL, Cannon-Albright LA
    Breast cancer histologic subtypes show excess familial clustering.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32198.
    >> Share

  157. LIU Y, West R, Weber JD, Colditz GA, et al
    Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32200.
    >> Share

  158. NYROP KA, Deal AM, Reeder-Hayes KE, Shachar SS, et al
    Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Cancer. 2019 May 15. doi: 10.1002/cncr.32175.
    >> Share

  159. NAJJAR YG, Puligandla M, Lee SJ, Kirkwood JM, et al
    An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32162.
    >> Share

  160. DEMISSEI BG, Finkelman BS, Hubbard RA, Zhang L, et al
    Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy.
    Cancer. 2019 May 1. doi: 10.1002/cncr.32149.
    >> Share

    April 2019
  161. HAWKINS BRESSLER L, Mersereau JE, Anderson C, Rodriguez JL, et al
    Fertility-related experiences after breast cancer diagnosis in the Sister and Two Sister Studies.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32126.
    >> Share

  162. LYNCH BM, Nguyen NH, Moore MM, Reeves MM, et al
    A randomized controlled trial of a wearable technology-based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer survivors: The ACTIVATE Trial.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32143.
    >> Share

  163. PRINTZ C
    Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Cancer. 2019;125:1213.
    >> Share

  164. PRINTZ C
    Circulating tumor cell count could be used to determine treatment of metastatic breast cancer.
    Cancer. 2019;125:1021.
    >> Share

  165. PRINTZ C
    First person profile: Olufunmilayo "Funmi" Olopade, MD, FACP: An expert in cancer genetics, Dr. Olopade has spent her career helping to fight the disease on multiple continents.
    Cancer. 2019;125:1019-1021.
    >> Share

    March 2019
  166. PRINTZ C
    Study projects a 43% increase in lung cancer mortality among women: New research suggests that, among women, strides in reducing global deaths from breast cancer could be tempered by rising lung cancer deaths. However, according to experts, the projec
    Cancer. 2019;125:831-832.
    >> Share

  167. GLADDY RA, Wunder JS
    Risk-stratified surveillance in dermatofibrosarcoma protuberans: Less is more.
    Cancer. 2019;125:670-672.
    >> Share

  168. HUIS IN 'T VELD EA, van Coevorden F, Grunhagen DJ, Smith MJ, et al
    Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated?
    Cancer. 2019;125:735-741.
    >> Share

    February 2019
  169. PRINTZ C
    Skin cancer prevention advocates target indoor tanning: As tanning beds increasingly turn up outside of traditional salons, experts are trying innovative approaches to curb their use.
    Cancer. 2019;125:493-494.
    >> Share

  170. GIANNAKEAS V, Narod SA
    The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32008.
    >> Share

  171. DUFFY SW, Smith RA, Tabar L, Dean PB, et al
    Reply to The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32007.
    >> Share

  172. WINN AN, Dusetzina SB
    More evidence on the limited impact of state oral oncology parity laws.
    Cancer. 2019;125:335-336.
    >> Share

  173. PRINTZ C
    Black women less likely to adhere to hormone therapy for breast cancer.
    Cancer. 2019;125:331.
    >> Share

  174. FRANCIS DM, Witt JS, Anderson BM
    Indications for and efficacy of postmastectomy radiotherapy for patients with a favorable response to neoadjuvant chemotherapy.
    Cancer. 2019;125:332-334.
    >> Share

    January 2019
  175. GIBNEY GT, Atkins MB
    Choice of first-line therapy in metastatic melanoma.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31774.
    >> Share

  176. OTT PA, Pavlick AC, Johnson DB, Hart LL, et al
    A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31892.
    >> Share

  177. IBRAHEEM AF, Press DJ, Olopade OI, Huo D, et al
    Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
    Cancer. 2019;125:213-222.
    >> Share

  178. EYRE TA, Collins GP, Gupta A, Coupe N, et al
    A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
    Cancer. 2019;125:99-108.
    >> Share

    December 2018
  179. CHIN AL, Bentley JP, Pollom EL
    The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Cancer. 2018 Dec 19. doi: 10.1002/cncr.31910.
    >> Share

  180. APPENZELLER S, Gesierich A, Thiem A, Hufnagel A, et al
    The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31843.
    >> Share

  181. CHAN AA, Noguti J, Pak Y, Qi L, et al
    Interaction of body mass index or waist-to-hip ratio and sun exposure associated with nonmelanoma skin cancer: A prospective study from the Women's Health Initiative.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31810.
    >> Share

  182. HESTER LL, Park SI, Wood WA, Sturmer T, et al
    Cause-specific mortality among medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31821.
    >> Share

  183. SAAB KR, Mooradian MJ, Wang DY, Chon J, et al
    Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31889.
    >> Share

    November 2018
  184. BINES J, Tevaarwerk AJ
    Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31878.
    >> Share

  185. VAN DYK K, Crespi CM, Bower JE, Castellon SA, et al
    The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment.
    Cancer. 2018 Nov 28. doi: 10.1002/cncr.31858.
    >> Share

  186. FREY MK, Kopparam RV, Ni Zhou Z, Fields JC, et al
    Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Cancer. 2018 Nov 27. doi: 10.1002/cncr.31856.
    >> Share

  187. CARROLL JE, Van Dyk K, Bower JE, Scuric Z, et al
    Cognitive performance in survivors of breast cancer and markers of biological aging.
    Cancer. 2018 Nov 26. doi: 10.1002/cncr.31777.
    >> Share

  188. RESNICK MJ, Graves AJ, Gambrel RJ, Thapa S, et al
    The association between medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.
    Cancer. 2018 Nov 9. doi: 10.1002/cncr.31700.
    >> Share

  189. KALINSKY K, O'Regan RM
    Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
    Cancer. 2018 Nov 2. doi: 10.1002/cncr.31814.
    >> Share

  190. GREENWALD MK, Ruterbusch JJ, Beebe-Dimmer JL, Simon MS, et al
    Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Cancer. 2018 Nov 2. doi: 10.1002/cncr.31798.
    >> Share

  191. BHATTY M, Kato S, Piha-Paul SA, Naing A, et al
    Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies.
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31812.
    >> Share

  192. MAILHOT VEGA RB, Balogun OD, Ishaq OF, Bray F, et al
    Estimating child mortality associated with maternal mortality from breast and cervical cancer.
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31780.
    >> Share

    October 2018
  193. CAUDLE AS, Kuerer HM, Krishnamurthy S, Shin K, et al
    Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31825.
    >> Share

  194. LAMBERTINI M, Martel S, Campbell C, Guillaume S, et al
    Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Cancer. 2018 Oct 18. doi: 10.1002/cncr.31784.
    >> Share

  195. LANDEIRO LCG, Gagliato DM, Fede AB, Fraile NM, et al
    Return to work after breast cancer diagnosis: An observational prospective study in brazil.
    Cancer. 2018 Oct 17. doi: 10.1002/cncr.31735.
    >> Share


  196. Older melanoma patients may respond better to anti-PD1 immunotherapy.
    Cancer. 2018;124:3961.
    >> Share

  197. HOSKINS KF, Tejeda S, Vijayasiri G, Chukwudozie IB, et al
    A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31635.
    >> Share

  198. ROCQUE GB, Williams CP, Kenzik KM, Jackson BE, et al
    Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
    Cancer. 2018 Oct 14. doi: 10.1002/cncr.31694.
    >> Share

  199. ROMANOFF A, Zabor EC, Petruolo O, Stempel M, et al
    Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?
    Cancer. 2018 Oct 11. doi: 10.1002/cncr.31757.
    >> Share

  200. TARHINI AA, Frankel P, Ruel C, Ernstoff MS, et al
    NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31734.
    >> Share

  201. CHLEBOWSKI RT, Luo J, Anderson GL, Barrington W, et al
    Weight loss and breast cancer incidence in postmenopausal women.
    Cancer. 2018 Oct 8. doi: 10.1002/cncr.31687.
    >> Share

  202. ANDERSON C, Nichols HB, Deal AM, Mark Park YM, et al
    Changes in cardiovascular disease risk and risk factors among women with and without breast cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31775.
    >> Share

  203. PERNAS S, Barroso-Sousa R, Tolaney SM
    Optimal treatment of early stage HER2-positive breast cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31657.
    >> Share

  204. GORNICK MC, Kurian AW, An LC, Fagerlin A, et al
    Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.
    Cancer. 2018 Oct 5. doi: 10.1002/cncr.31731.
    >> Share

  205. JETER JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, et al
    Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials.
    Cancer. 2018 Oct 3. doi: 10.1002/cncr.31719.
    >> Share

    September 2018
  206. KEHL KL, Niu J, Chavez-MacGregor M, Giordano SH, et al
    Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
    Cancer. 2018 Sep 28. doi: 10.1002/cncr.31760.
    >> Share

  207. KIM SJ, Glassgow AE, Watson KS, Molina Y, et al
    Gendered and Racialized Social Expectations, Barriers, and Delayed Breast Cancer Diagnosis.
    Cancer. 2018 Sep 24. doi: 10.1002/cncr.31636.
    >> Share

  208. GOLDSTEIN AM, Stidd KC, Yang XR, Fraser MC, et al
    Pediatric Melanoma in Melanoma-Prone Families.
    Cancer. 2018 Sep 12. doi: 10.1002/cncr.31641.
    >> Share

  209. GUO F, Kuo YF, Shih YCT, Giordano SH, et al
    Trends in Breast Cancer Mortality by Stage at Diagnosis Among Young Women in the United States.
    Cancer. 2018 Sep 6. doi: 10.1002/cncr.31638.
    >> Share


  210. MINDACT study results show low risk of local recurrence after 5 years for patients with early breast cancer.
    Cancer. 2018;124:3466-3467.
    >> Share


  211. First person: George Sledge, Jr, MD: Former ASCO president leads breast cancer research and mentors Stanford faculty.
    Cancer. 2018;124:3465.
    >> Share

    August 2018

  212. Many Women With the Most Common Form of Breast Cancer Can Skip Chemotherapy: Study finds that approximately 70% of patients with this form of the disease do not need adjuvant chemotherapy.
    Cancer. 2018;124:3281-2382.
    >> Share

    July 2018
  213. JAGSI R, Ward KC, Abrahamse PH, Wallner LP, et al
    Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer.
    Cancer. 2018 Jul 23. doi: 10.1002/cncr.31532.
    >> Share

  214. FAJE AT, Lawrence D, Flaherty K, Freedman C, et al
    High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31629.
    >> Share

  215. DASH C, Taylor TR, Makambi KH, Hicks J, et al
    Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE study.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31569.
    >> Share

  216. PRINTZ C
    Older women with a family history of breast cancer face increased risk of the disease.
    Cancer. 2018;124:2673.
    >> Share

    June 2018
  217. BAIL JR, Fruge AD, Cases MG, De Los Santos JF, et al
    A home-based mentored vegetable gardening intervention demonstrates feasibility and improvements in physical activity and performance among breast cancer survivors.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31559.
    >> Share

  218. FRANK RD, Winham SJ, Vierkant RA, Frost MH, et al
    Evaluation of 2 breast cancer risk models in a benign breast disease cohort.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31528.
    >> Share

    May 2018
  219. VALACHIS A, Mamounas EP, Mittendorf EA, Hayashi N, et al
    Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31518.
    >> Share

    April 2018
  220. KARUTURI MS, Holmes HM, Lei X, Johnson M, et al
    Potentially inappropriate medication use in older patients with breast and colorectal cancer.
    Cancer. 2018 Apr 24. doi: 10.1002/cncr.31403.
    >> Share

  221. SHUMWAY DA, Griffith KA, Hawley ST, Wallner LP, et al
    Patient views and correlates of radiotherapy omission in a population-based sample of older women with favorable-prognosis breast cancer.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31378.
    >> Share

  222. DAVIS EJ, Johnson DB, Sosman JA, Chandra S, et al
    Melanoma: What do all the mutations mean?
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31345.
    >> Share

  223. TURK AA, Wisinski KB
    PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31307.
    >> Share

  224. OLAGUNJU TO, Liu Y, Liang LJ, Stomber JM, et al
    Disparities in the survivorship experience among Latina survivors of breast cancer.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31342.
    >> Share

  225. SCOTT JM, Iyengar NM, Nilsen TS, Michalski M, et al
    Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31368.
    >> Share

    March 2018
  226. GOLD KA, Kies MS, William WN Jr, Johnson FM, et al
    Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31346.
    >> Share

  227. TSAI KK, Bollin KB, Patel SP
    Obstacles to improving outcomes in the treatment of uveal melanoma.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31284.
    >> Share

  228. UEMURA MI, French JT, Hess KR, Liu D, et al
    Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31336.
    >> Share

  229. PRINTZ C
    First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Cancer. 2018;124:1097-1098.
    >> Share

  230. LEHRER S, Rheinstein PH, Rosenzweig KE
    Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31262.
    >> Share

  231. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31261.
    >> Share

  232. SCHWARTZ KL, Simon MS, Bylsma LC, Ruterbusch JJ, et al
    Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Cancer. 2018 Mar 5. doi: 10.1002/cncr.31299.
    >> Share

  233. FREEDMAN RA, Keating NL, Lin NU, Winer EP, et al
    Breast cancer-specific survival by age: Worse outcomes for the oldest patients.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31308.
    >> Share

    February 2018
  234. PRINTZ C
    Patients with breast cancer who are treated with chemotherapy risk long-term nerve damage.
    Cancer. 2018;124:663.
    >> Share

  235. EKENGA CC, Perez M, Margenthaler JA, Jeffe DB, et al
    Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls.
    Cancer. 2018 Feb 13. doi: 10.1002/cncr.31270.
    >> Share

  236. KWA MJ, Adams S
    Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Cancer. 2018 Feb 9. doi: 10.1002/cncr.31272.
    >> Share

    January 2018
  237. LITVAK A, Batukbhai B, Russell SD, Tsai HL, et al
    Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31260.
    >> Share

  238. REEDER-HAYES KE, Wheeler SB, Baggett CD, Zhou X, et al
    Influence of provider factors and race on uptake of breast cancer gene expression profiling.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31222.
    >> Share

  239. SIMON MS, Beebe-Dimmer JL, Hastert TA, Manson JE, et al
    Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31230.
    >> Share

  240. SHURELL E, Olcese C, Patil S, McCormick B, et al
    Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
    Cancer. 2018;124:46-54.
    >> Share

    December 2017
  241. ARUN BK, Gutierrez Barrera AM, Ueno NT
    Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31188.
    >> Share

  242. ALTUNDAG K
    Diagnosis of patients with inflammatory breast cancer is a problematic issue.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31189.
    >> Share

  243. MILLER JW, Smith JL, Ryerson AB, Tucker TC, et al
    Disparities in breast cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5100-5118.
    >> Share

  244. ROSENSTOCK AS, Niu J, Giordano SH, Zhao H, et al
    Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Cancer. 2017 Dec 13. doi: 10.1002/cncr.31144.
    >> Share

  245. OHRI N, Haffty BG, Buchholz TA
    The role of postmastectomy radiotherapy in patients with stage II breast cancer.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31130.
    >> Share

  246. NIXON NA, Khan OF, Imam H, Tang PA, et al
    Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Cancer. 2017;123:4672-4679.
    >> Share

    November 2017
  247. MANNEVILLE F, Rotonda C, Conroy T, Bonnetain F, et al
    The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.
    Cancer. 2017 Nov 8. doi: 10.1002/cncr.31108.
    >> Share

  248. OHRI N, Sittig MP, Tsai CJ, Hwang ES, et al
    Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31080.
    >> Share

  249. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    >> Share

    October 2017
  250. WALLACE AS, Keene KS, Williams CP, Jackson BE, et al
    Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.30989.
    >> Share

  251. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    >> Share

  252. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    >> Share

  253. GUTIERREZ BARRERA AM, Fouad TM, Song J, Webster R, et al
    BRCA mutations in women with inflammatory breast cancer.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31069.
    >> Share

  254. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    >> Share

  255. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    >> Share

  256. DONALDSON AR, McCarthy C, Goraya S, Pederson HJ, et al
    Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31061.
    >> Share

  257. JAGSI R, Abrahamse PH, Lee KL, Wallner LP, et al
    Treatment decisions and employment of breast cancer patients: Results of a population-based survey.
    Cancer. 2017 Oct 9. doi: 10.1002/cncr.30959.
    >> Share

  258. ARLEO EK, Hendrick RE, Helvie MA, Sickles EA, et al
    Comparison of recommendations for screening mammography using CISNET models.
    Cancer. 2017;123:3673-3680.
    >> Share

    September 2017
  259. CHAOUL A, Milbury K, Spelman A, Basen-Engquist K, et al
    Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.30938.
    >> Share

  260. HARTMAN SJ, Nelson SH, Myers E, Natarajan L, et al
    Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study.
    Cancer. 2017 Sep 19. doi: 10.1002/cncr.30987.
    >> Share

  261. NGUYEN KH, Pasick RJ, Stewart SL, Kerlikowske K, et al
    Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups.
    Cancer. 2017;123:3468-3475.
    >> Share

  262. KAROL SE, Yang W, Smith C, Cheng C, et al
    Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.
    Cancer. 2017;123:3602-3608.
    >> Share

  263. STURGEON KM, Hackley R, Fornash A, Dean LT, et al
    Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30935.
    >> Share

    August 2017
  264. SENNERSTAM RB, Franzen BSH, Wiksell HOT, Auer GU, et al
    Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.
    Cancer. 2017 Aug 24. doi: 10.1002/cncy.21909.
    >> Share

  265. MASTELLARO MJ, Seidinger AL, Kang G, Abrahao R, et al
    Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
    Cancer. 2017;123:3150-3158.
    >> Share

  266. MARMOR S, Hui JYC, Huang JL, Kizy S, et al
    Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Cancer. 2017;123:3015-3021.
    >> Share

  267. HAWLEY ST, Griffith KA, Hamilton AS, Ward KC, et al
    The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients.
    Cancer. 2017 Aug 15. doi: 10.1002/cncr.30924.
    >> Share

  268. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    >> Share

  269. VAZ-LUIS I, O'Neill A, Sepucha K, Miller KD, et al
    Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
    Cancer. 2017;123:2821-2828.
    >> Share

    July 2017
  270. POWIS M, Sutradhar R, Gonzalez A, Enright KA, et al
    Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30804.
    >> Share

    June 2017
  271. TARAZI WW, Bradley CJ, Bear HD, Harless DW, et al
    Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment.
    Cancer. 2017 Jun 26. doi: 10.1002/cncr.30771.
    >> Share

  272. WALLNER LP, Li Y, McLeod MC, Hamilton AS, et al
    Decision-support networks of women newly diagnosed with breast cancer.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30848.
    >> Share

  273. ABRAHAMS HJG, Gielissen MFM, Donders RRT, Goedendorp MM, et al
    The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30815.
    >> Share

    May 2017
  274. KOROUKIAN SM, Bakaki PM, Htoo PT, Han X, et al
    The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio's underserved women.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30720.
    >> Share

  275. BROWNE JP, Jeevan R, Gulliver-Clarke C, Pereira J, et al
    The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer.
    Cancer. 2017 May 17. doi: 10.1002/cncr.30788.
    >> Share

  276. PRINTZ C
    Genomic sequencing of treatment-resistant metastatic breast cancer reveals key alterations.
    Cancer. 2017;123:904.
    >> Share

  277. PRINTZ C
    Artificial intelligence platform for oncology could assist in treatment decisions.
    Cancer. 2017;123:905.
    >> Share

    April 2017
  278. HSU CD, Wang X, Habif DV Jr, Ma CX, et al
    Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.
    Cancer. 2017 Apr 25. doi: 10.1002/cncr.30722.
    >> Share

  279. KATZ SJ, Wallner LP, Abrahamse PH, Janz NK, et al
    Treatment experiences of Latinas after diagnosis of breast cancer.
    Cancer. 2017 Apr 11. doi: 10.1002/cncr.30702.
    >> Share

  280. LIANG X, Margolis KL, Hendryx M, Reeves K, et al
    Effect of depression before breast cancer diagnosis on mortality among postmenopausal women.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30688.
    >> Share

  281. CASSIDY RJ, Liu Y, Kahn ST, Jegadeesh NK, et al
    The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30675.
    >> Share

  282. PRINTZCANCER C
    Breast cancer mortality rates decline internationally, with some major exceptions.
    Cancer. 2017;123:1085.
    >> Share

  283. PRINTZCANCER C
    Study to examine genetic factors behind increased risk of breast cancer in African Americans.
    Cancer. 2017;123:1083-1084.
    >> Share

    March 2017
  284. HENRY NL, Braun TM, Breslin TM, Gorski DH, et al
    Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30674.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016